ストックスクリーナーアプリを入手
1.99
17.43%
-0.42
前日終値:
$2.41
開ける：
$2.1
24時間の取引高:
1.12M
Relative Volume:
8.97
時価総額：
$55.48M
収益：
-
当期純損益:
$-14.14M
株価収益率:
-2.163
EPS:
-0.92
ネットキャッシュフロー:
$-12.64M
1週間 パフォーマンス:
-3.40%
1か月 パフォーマンス:
+16.37%
6か月 パフォーマンス:
+11.17%
1年 パフォーマンス:
-6.13%
1日の値動き範囲:
$1.90
$2.14
1週間の範囲:
$1.90
$2.50
52週間の値動き範囲:
$1.26
$2.71
Immix Biopharma Inc Stock (IMMX) Company Profile
名前
Immix Biopharma Inc
セクター
電話
(888) 958-1084
住所
11400 WEST OLYMPIC BLVD., LOS ANGELES
IMMX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
1.99 | 57.43M | 0 | -14.14M | -12.64M | -0.92 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Immix Biopharma Inc (IMMX) 最新ニュース
Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/Refractory AL Amyloidosis Trial Nexicart-2 - marketscreener.com
Immix Biopharma (IMMX) Expands NEXICART-2 Trial Sites | IMMX Stock News - GuruFocus
Immix Biopharma accelerates NEXICART-2 trial enrollment - Investing.com
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - marketscreener.com
Immix Amyloidosis Trial Surges: 10 New Sites Added, ASCO Data Presentation Coming - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Trading Up 15.3% – Should You Buy? - Defense World
Immix Biopharma reports promising trial results for NXC-201 - Investing.com Australia
Immix Biopharma reports promising trial results for NXC-201 By Investing.com - Investing.com India
Immix Biopharma Announces Positive Results for NXC-201 at - GlobeNewswire
Breakthrough AL Amyloidosis Treatment Achieves 71% Complete Response Rate in First US Trial at ASCO - Stock Titan
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling ... - Eagle-Tribune
Immix Biopharma to Host KOL Event to Discuss NXC-201 - GlobeNewswire
We're Keeping An Eye On Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate - Yahoo Finance
Immix Biopharma — Steady progress in Q125 - Smartkarma
Immix Biopharma Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Immix Biopharma (IMMX) to Release Earnings on Thursday - Defense World
Favourable Signals For Immix Biopharma: Numerous Insiders Acquired Stock - simplywall.st
Immix Biopharma Announces Oral Presentation of NXC-201 Phase 1/2 Trial Data at ASCO 2025 - Nasdaq
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025 - GlobeNewswire
Groundbreaking CAR-T Therapy for AL Amyloidosis: First US Trial Data Earns Prestigious ASCO Spotlight - Stock Titan
Immix Biopharma — All eyes on NEXICART-2 - Smartkarma
Immix Biopharma (IMMX) Expected to Announce Earnings on Friday - Defense World
Immix Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Immix Biopharma Inc. (IMMX) reports earnings - Quartz
Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Thursday - Defense World
Immix Biopharma — NXC-201 receives FDA RMAT designation - Smartkarma
SBI Securities Co. Ltd. Purchases New Stake in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Immix Biopharma (NASDAQ:IMMX) Trading Down 9% – Here’s Why - Defense World
HC Wainwright Reaffirms Buy Rating for Immix Biopharma (NASDAQ:IMMX) - MarketBeat
FDA Awards RMAT Designation to NXC-201 for Relapsed/Refractory AL Amyloidosis - OncLive
Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright - MSN
Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com South Africa
Immix Biopharma’s (IMMX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Immix Biopharma’s CAR-T NXC-201 Snags FDA RMAT Designation for Light Chain Amyloidosis - CGTLive™
Buy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201 - TipRanks
Immix Biopharma Says FDA Grants Regenerative Medicine Advanced Therapy Designation to NXC-201 Cell Therapy - Marketscreener.com
Immix Biopharma Receives FDA RMAT Designation For NXC-201 -February 10, 2025 at 10:15 am EST - Marketscreener.com
Think Lucid Group is Expensive? This Chart Might Change Your Mind. - The Globe and Mail
Immix Biopharma Receives FDA Regenerative Medicine Advanced - GlobeNewswire
Breakthrough: IMMX Secures Elite FDA Status for First-Ever AL Amyloidosis CAR-T Treatment - StockTitan
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 - The Globe and Mail
Immix Biopharma : Presentation (IMMX Corporate presentation February 2025) - Marketscreener.com
Is Qualcomm Stock a Buy Even Without Huawei Deal? - The Globe and Mail
Several Insiders Invested In Immix Biopharma Flagging Positive News - Yahoo Finance
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 11.0% in December - MarketBeat
Geode Capital Management LLC Has $224,000 Stock Holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
FY2024 EPS Estimate for Immix Biopharma Lowered by Analyst - Defense World
HC Wainwright Predicts Weaker Earnings for Immix Biopharma - MarketBeat
Immix Biopharma Inc (IMMX-Q) QuotePress Release - The Globe and Mail
Immix Biopharma, Inc. Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T - Marketscreener.com
HC Wainwright Reaffirms “Buy” Rating for Immix Biopharma (NASDAQ:IMMX) - Defense World
Immix Biopharma Inc (IMMX) 財務データ
収益
当期純利益
現金流量
EPS
Immix Biopharma Inc (IMMX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hsu Jason | Director |
Dec 20 '24 |
Buy |
2.17 |
7,700 |
16,678 |
853,000 |
| Hsu Jason | Director |
Aug 21 '24 |
Buy |
2.23 |
15,000 |
33,390 |
837,200 |
| Hsu Jason | Director |
Aug 22 '24 |
Buy |
2.25 |
8,100 |
18,233 |
845,300 |
| Ng Carey | Director |
Aug 16 '24 |
Buy |
1.86 |
10,000 |
18,600 |
20,000 |
| Hsu Jason | Director |
Jul 24 '24 |
Buy |
2.15 |
6,000 |
12,877 |
822,200 |
| Hsu Jason | Director |
Jul 18 '24 |
Buy |
2.07 |
3,200 |
6,639 |
816,200 |
| Rachman Ilya M | CEO and Chairman |
Jun 07 '24 |
Buy |
2.13 |
2,600 |
5,538 |
1,136,259 |
| Morris Gabriel S | CFO |
Jun 07 '24 |
Buy |
2.12 |
2,500 |
5,298 |
285,834 |
| Morris Gabriel S | CFO |
Jun 04 '24 |
Buy |
1.81 |
3,300 |
5,973 |
283,334 |
| Rachman Ilya M | CEO and Chairman |
Jun 04 '24 |
Buy |
1.81 |
3,300 |
5,970 |
1,133,659 |
17.27%
1.06%
大文字化:
|
ボリューム (24 時間):